

PRESS RELEASE – FOR IMMEDIATE DIFFUSION

IntegraGen, Inc. Names Michael Dresner, National Sales Director

CAMBRIDGE, MA (APRIL 17, 2012) -- IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, has named Michael E. Dresner National Sales Director. He will be responsible for IntegraGen's sales efforts in the U.S. associated with the ARISK™ Autism Risk Assessment Test.

"We are very pleased to welcome Mr. Dresner," says Dr. Bernard Courtieu, chairman and chief executive officer of IntegraGen, SA. "His extensive sales experience and expertise in the field of molecular diagnostics will be a valuable addition to our team."

Mr. Dresner will spearhead sales efforts for IntegraGen's ARISK Test, a gender specific, genetic screening test that looks at 65 genetic markers associated with Autism Spectrum Disorder (ASD). The test is designed to assess the risk of autism in children from multiplex families—siblings of children with ASD who are 6 to 30 months of age, paving the way to early clinical diagnosis and early intervention, which can lead to significant improvement in IQ scores, language and social skills, and ensure best possible outcomes. The ARISK Test is available only through medical professionals, including pediatricians, developmental pediatricians, child neurologists and autism clinicians

Mr. Dresner brings more than a decade of sales experience in the field of molecular diagnostics testing services. Most recently, he was Director of Client and Patient Services for Oxford Immunotec, Inc. Before that, he was National Accounts Manager for Anatomical Pathology Instruments and Consumables at Thermo Fisher Scientific, and held several positions at Athena Diagnostics, including Director of Corporate Accounts and National Sales Trainer. Mr. Dresner also served as a Sales Representative for GlaxoSmithKline Pharmaceuticals and Novartis Pharmaceuticals.

Mr. Dresner has a Bachelor of Science degree in marketing from Syracuse University.

About IntegraGen:

Integragen SA of Evry, France-based IntegraGen (ALINT.PA), is a biotechnology company dedicated to gene discovery. The Company's wholly-owned US subsidiary is located in Cambridge, Massachusetts. The Company's goal is the development of molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment and therapy for complex debilitating diseases. Its Genetic Services Business provides state-of-the-art genotyping services to the research community. IntegraGen has also made inroads in identifying a number of common genetic variants associated with ASD. The Company has recently launched the ARISK Test in the United States providing a genetic screening tool for the early identification of children at risk for autism spectrum disorder (ASD).

###

Full year 2011 financial results will be published on the 23rd of April 2012,
Before market

CONTACTS



INTEGRAGEN

Bernard Courtieu
CEO
Tel.: +33 (0)1 60 91 09 00

Laurence Riot Lamotte
CFO
contact@integragen.com
Tel.: +33 (0)1 60 91 09 09

NEWCAP.

Investors and Media relationship

Axelle Vuillermet / Nicolas Merigeau
integragen@newcap.fr
Tel.: +33 (0)1 44 71 94 93